Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) - Kümmel, Sherko; Schneeweiss, Andreas (European journal of cancer, 2017)
Gesehen am 27.11.2018